Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × zimberelimab × 1 year × Clear all

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04736173 2026-03-30

ARC-10

Phase 2 Active not recruiting

169 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

270 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

1,021 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04791839 2025-11-05

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

94 enrolled

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT04262856 2025-08-26

ARC-7

Phase 2 Completed

151 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

ARC-25

ARC-10

VELOCITY-Lung

STAR-121

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

ARC-12

ARC-7